Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial - Qin, S; Li, Q; Gu, S (Lancet Gastroenterol Hepatol, 2021)